Ahmadi-Simab, K., Lamprecht, P., Jankowiak, C. and Gross, W.L. (2006) Successful Treatment of Refractory Adult Onset Still’s Disease with Rituximab. Annals of the Rheumatic Diseases, 65, 1117-1118.
http://dx.doi.org/10.1136/ard.2005.047621

has been cited by the following article:

• TITLE: Adult Onset Still’s Disease

  AUTHORS: Madiha Mahfoudhi, Imen Gorsane, Rafik Shimi, Sami Turki, Taieb Ben Abdallah

  KEYWORDS: Adult Onset Still’s Disease, Cytokine, TNF Alpha Receptor Antagonist, Interleukin 6 Receptor Antagonist, Interleukin 1 Receptor Antagonist

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.6 No.10, October 13, 2015

  ABSTRACT: The adult onset Still’s disease is a rare affection characterised by occurrence of fever, arthralgia or arthritis and evanescent cutaneous eruption. Multiple other systemic lesions make the diagnosis more difficult. Several diagnostic criteria were formulated to confirm this disease. The physiopathology of the adult onset Still’s disease is not well elucidated. However, several studies based on new facts in physiopathology, improved the therapy of refractory forms for which the biotherapy was an interesting alternative. The TNF alpha receptor antagonists are efficient on systemic and articular manifestations of this disease and allow a corticosteroid’s saving. Tocilizumab (interleukin 6 receptor antagonist), and Anakinra (interleukin 1 receptor antagonist) are also new promising treatments for resistant forms.